VISION, MISSION & STRATEGY
REMAINING RESPONSIVE TO EVOLVING RESEARCH AND PATIENT NEEDS
DNDi is rooted in an ideal: to mobilize scientific innovation to create new medicines for the world’s most neglected diseases and malaria. Our aim was to provide the structure to take the most promising projects ignored by commercial drug development through the pipeline, by capitalizing on existing capacity and expertise, particularly in affected countries.
Message from Prof Marcel Tanner, Chair of the Board of Directors, and Dr Bernard Pécoul, Executive Director
Since its inception in 2003, DNDi has defined itself as an experiment in ‘innovation for access,’ a laboratory for alternative mechanisms that deliver affordable products answering to an unaddressed medical need. Our scale is by definition small: our purpose is not, and never has been, to act as the solution to systemic failures of biomedical R&D.
Our six achievements to date, attained in collaboration with our partners, bear witness to the pertinence of that initial ideal and the success of the model – with two new antimalarial fixed-dose combinations, the world’s first child-friendly medication for Chagas disease, and changes to national or international guidelines, thanks to successful clinical trials for sleeping sickness and for visceral leishmaniasis treatments in Africa and Asia. More than a decade later, it is our pleasure to take stock once again.
4 › DNDi Annual Report 2015